Background: Pegylated liposomal doxorubicin (PL-DOX) has been shown in preclinical models to induce less cardiotoxicity than non-liposomal doxorubicin. Endomyocardial biopsy is a highly sensitive and specific method for detecting anthracyclineinduced cardiac damage.
Introduction
The anthracyclines are among the most effective anticancer drugs developed to date, but their use is limited by cardiotoxicity. Although this may be manifested by a variety of relatively benign arrhythmias and non-specific ST-Twave changes, the most serious form of this toxicity consists of a cardiomyopathy that increases in frequency with higher cumulative doses. While there are a number of hypotheses suggesting mechanisms for this myocardial damage, the high peak plasma level of drug accompanying a standard 15-30-minute infusion of doxorubicin every three weeks is believed to be an important contributory factor [1] . This is supported by evidence that dosing schedules designed to lower peak plasma concentration reduce cardiotoxicity [1, 2] . Liposomal encapsulation of anthracyclines is another method of lowering peak plasma concentration, and it has been shown in a number of animal models that this reduces cardiotoxicity, too [3] .
Pegylated liposomal doxorubicin (PL-DOX) is a unique polymer-coated liposomal formulation (STEALTH®). The polymer groups alter the pharmacokinetics of the pegylated liposomes, permitting them to circulate for much longer periods than conventional liposomes [3] [4] [5] . Like other liposomes, these are associated with a lower peak level of bioavailable drug. Unlike other liposomes, pegylated liposomes are preferentially delivered to tissues with new vasculature (such as tumors), so that there may also be less exposure of normal tissues to doxorubicin. Accordingly, histological examination of heart tissue indicates that PL-DOX causes less morphological changes relative to free doxorubicin in rats, dogs and rabbits [6] .
Doxorubicin is often used in combination with bleomycin and/or vincristine (ABV) in the treatment of advanced AIDS-related Kaposi's sarcoma (KS). In clinical trials comparing PL-DOX and combination regimens as first-and second-line treatment for advanced KS, PL-DOX provided significantly superior tumor response and fewer and less severe side effects relative to ABV or BV [7, 8] . PL-DOX-related cardiac adverse events in these trials were infrequent, but cumulative doses were generally lower than the 450 mg/m 2 regarded as the threshold for anthracycline-related cardiomyopathy.
Non-invasive methods such as left ventricular ejection fraction (LVEF) and clinical evaluation have been used most frequently to identify heart failure [9] . However, considerable irreversible heart damage must occur before these tests become abnormal, and factors other than anthracycline damage may contribute to the cardiac dysfunction [10, 11] . In contrast, unique anthracyclineinduced histologic changes may be identified by biopsy early in the development of cardiomyopathy, allowing specific and quantifiable detection of anthracyclinemediated damage even in the presence of other causes of heart damage [12] . This paper reports the results of endomyocardial biopsies performed on patients who received doses of PL-DOX in excess of 400 mg/m 2 for the treatment of KS. These results are compared to historical series of patients treated with doxorubicin on two dose schedules (20 mg/m 2 weekly and 60 mg/m 2 every three weeks) and biopsied at Stanford University Medical Center. Analysis of risk factors for anthracycline cardiotoxicity suggests that factors which contribute to the severity of anthracycline-induced histopalhological changes and factors which contribute to the expression of congestive heart failure are not exactly the same. Only cumulative doxorubicin dose, doxorubicin dose schedule (60 mg/m 2 every three weeks vs. 20 mg/m 2 week) and prior cardiac radiotherapy correlate significantly with histological damage detected by biopsy [13, 15] . Since none of the KS patients had received cardiac irradiation, all patients in the historical database that had received cardiac irradiation were excluded from this study. The eligible controls included 100 patients. The clinical characteristics of these patients are shown in Table 1. Two control groups were then assembled. First, each PL-DOX treated patient was matched to the single patient among the 100 potential matches that most closely approximated the patient's cumulative doxorubicin dose (control group I). When more than one doxorubicin patient was identified with a cumulative dose within 5 mg/m 2 of that of the PL-DOX patient, patients with a matching peak dose of 20 mg/m 2 were preferentially chosen. In the second comparison, the PL-DOX group was compared to the 24 patients treated with doxorubicin at 20 mg/m 2 /wk (control group 2). [16, 17] . The specimens obtained during each biopsy procedure in both groups were processed as described by Mason et al. [10] .
Patients and methods

Patient
For the patients in control group 1, prints of electron micrographs were retrieved from medical records. Both these and the newer prints from the case records of PL-DOX patients were scanned into computer files, and thus any differences among the prints due to aging were indistinguishable when the images were viewed on a computer monitor. Micrographs from PL-DOX patients and control group 1 were randomized and read blinded by two pathologists. A total of 28 case files were randomized: the 10 PL-DOX patients, the 10 matched doxorubicin controls, and eight other near matches. A consensus morphologic grade was derived for each of the 28 sets of micrographs based on a seven-point scale previously described by Billingham et al. [11] (see Table 2 ). Scores for control group 2 were used as found in the historical database.
Patients receiving PL-DOX were also evaluated for evidence of idiopathic lymphocytic myocarditis, opportunistic infection and other HIV-related changes.
Statistical analysis
The comparison of the biopsy scores between the PL-DOX group and the two control groups was performed using the Cochran-MantelHaenszel method for testing the row mean scores difference. This nonparametric test was controlled for patient-matching. The comparison of the biopsy scores between the PL-DOX group and the control group 2 was performed by using the non-parametric Wilcoxon rank-sum test. 
Results
The clinical characteristics of the PL-DOX and control group patients are listed in Table 1 . All PL-DOX patients were male with a median age of 38 years (range 32-51), reflecting characteristics expected of the Kaposi's sarcoma population. Eight of the ten PL-DOX patients had left ventricular ejection fraction or fractional shortening measurements. All baseline values were within the normal range. The ejection fraction of PL-DOX patient 9 dropped from 60% at baseline to 40% after a cumulative dose of 554 mg/m 2 . No cardiac function data are available for PL-DOX patients 3 and 10. The median age of the control group 1 patients was '56 years (range 31-68) with four females and six males. Half the patients in this group received concurrent cyclophosphamide. None of the control patients had cardiac ejection fraction determinations. The groups were similar in other regards.
None of the cardiac biopsies from the PL-DOX patients showed evidence of myocarditis, opportunistic infection, cardiomyopathy or involvement by Kaposi's sarcoma or other malignancies.
Transient atrial fibrillation occurred in one PL-DOX patient during biopsy. It resolved spontaneously, and no other adverse events associated with the procedure were observed. Hemodynamic measurements recorded during biopsy were within normal ranges.
The biopsy scores of each of the matched PL-DOX and control group 1 patients are shown in Table 3 . The paired cumulative doses are within 5 mg/m 2 of each other for five of the pairs. For the other five, the patient treated with PL-DOX received 25 to 236 mg/m 2 more doxorubicin than the control patient. Similar data comparing the PL-DOX patients with the 24 patients in control group 2 are shown in Table 4 . Only two of the patients treated with doxorubicin at 20 mg/m 2 /week matched a PL-DOX patient with a cumulative dose within ± 5 mg/m 2 . The mean and median cumulative doses of PL-DOX were higher than those of either control group. The biopsy data are plotted in Figure 1 . The median biopsy score for the PL-DOX patients was 0.3 (range 0.0-1.5), compared to 3.0 (range 1.5-3.0) for control group 1 and 1.25 (range 0.0-3.0) for control group 2. Comparison of the PL-DOX and control group 1 biopsy scores, based on the rank scores of the biopsy results, indicated a significant difference (P = 0.002) between the two groups. The comparison with control group 2 also indicated a significant difference (P < 0.001) between the PL-DOX group and the doxorubicin patients.
Discussion
Successful attempts at circumventing or preventing the cardiotoxicity of anthracyclines while preserving their antitumor benefit have included the administration of continuous infusions or lower doses at more frequent intervals; the development of anthracycline analogues; the use of agents that may selectively block doxorubicin cardiotoxicity; and now the use of liposomes [2, 9, 13, 18, 19] . That lower doses of doxorubicin at more frequent intervals are associated with reduced cardiotoxicity is widely accepted and is based almost entirely on relatively small cardiac biopsy studies [2, 13, [20] [21] [22] . The high sensitivity and power displayed in these studies provided the inspiration for the present study, in which endomyocardial biopsies of patients receiving PL-DOX or doxorubicin are compared. Cumulative dose of anthracycline is the single most important factor determining cardiac toxicity [13, 15] . Thus, Control group 1 was chosen based on matched cumulative dose. In this first analysis comparing endomyocardial biopsies of PL-DOX and doxorubicin patients, PL-DOX patients appeared to incur less histopathological change than patients receiving free doxorubicin. The highest cumulative dose given to any patient in control Table 4 . Comparison of biopsy scores from patients treated with PL-DOX or doxorubicin at equivalent peak dose (control group 2). group 1 was 671 mg/m 2 but three patients treated with PL-DOX received significantly higher doses, the highest level reached being 860 mg/m 2 . Despite the higher cumulative dose, the median biopsy score of PL-DOX patients was significantly lower than that of the doxorubicin controls, with a median of 0.3 compared to 3.0 for control group 1 (P = 0.002).
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The most important factor in the development of anthracycline cardiotoxicity after cumulative dose is the size of the administered bolus [13, 15] . The closest comparison in this regard is PL-DOX at 20 mg/m 2 biweekly with doxorubicin 20 mg/m 2 weekly (control group 2). The highest cumulative dose given to a control patient on this schedule was 645 mg/m 2 , and three PL-DOX patients received a higher cumulative dose > 645 mg/ m 2 . Although the median biopsy score in this control group (1.25) is lower than that of control group 1, it is still considerably higher than the PL-DOX patients. This difference exists despite sizable differences in the mean cumulative dose of the two patient groups; the PL-DOX patients received 204 mg/m 2 more of doxorubicin on average than patients in control group 2.
Although the results of the present study are promising, it has significant limitations that must be recognized. First, the present sample size is small, which limits its statistical power. This is especially pertinent due to reports of sampling bias in some biopsy studies [23] . The possibility of sampling bias is addressed in this study by taking multiple biopsies from each patient and subjecting them to an algorithm designed to identify the sections with the most advanced pathology [11, [24] [25] [26] . Distinct differences in age, frequency of hypertension, and treatment history may also hinder comparisons between the experimental and control groups. Although there is no evidence that these factors affect histological changes scored with myocardial biopsy, they have been implicated in the development of congestive heart failure.
The most important limitations, however, are introduced by differences in the dosing and scheduling of doxorubicin in the PL-DOX and control groups. Both doxorubicin and PL-DOX are effective for KS at lower dose rates than are usually employed when doxorubicin is used to treat other tumor types [5] . For this reason, no historical controls at exactly the same dose and schedule as PL-DOX are available. Although no study has identified dose rate as a risk factor for anthracycline cardiomyopathy, a bias due to differences in dose rate can not be ruled out. Although efforts were made to match patients with respect to the size of the administered dose (i.e., 20 mg/m 2 ), this was not always possible, which also introduces a bias in favor of PL-DOX. On the other hand, the average cumulative dose of PL-DOX was significantly higher in both analyses, and any bias related to cumulative dose should favor the control arms.
The evidence from this pilot study suggests that PL-DOX is less cardiotoxic than doxorubicin. Proof of this will require confirmatory studies. Choosing a setting in which to study the cardiotoxicity of PL-DOX is compli-cated by its unique pharmacokinetics and high activity. KS patients receiving doxorubicin at 20 mg/m 2 /two weeks would be a suitable control set, but, in light of the demonstrated superiority of PL-DOX to doxorubicin combinations in the treatment of KS, a randomized comparison of PL-DOX and doxorubicin in this disease is no longer ethically feasible [7, 8, 27] . While trials in solid tumors are ethically sound, formulation in pegylated liposomes fundamentally alters doxorubicin pharmacokinetics, precluding the administration of identical dose rates; dose-limiting toxicities are typically encountered at dose rates > 12.5 mg/m 2 /week of PL-DOX, compared to dose rates of > 20 mg/m 2 /week of doxorubicin typically used in solid tumors [28, 29] .
Ultimately, comparison of the relative cardiotoxicity of PL-DOX and doxorubicin should be made at equally efficacious dose-schedules, just as in the case of two distinct drugs. The pharmacokinetic changes engendered by encapsulating doxorubicin in a pegylated liposome lead to tumor-selective uptake in patients with solid tumors and KS [3] [4] [5] . PL-DOX alone induces a higher response rate than combinations, including doxorubicin containing combinations, conventionally used to treat KS [7, 8] . Practically, this means that a lower dose of PL-DOX may be as efficacious as a higher dose of doxorubicin. If this is true, it may be inappropriate to use identical dose schedules of PL-DOX and doxorubicin to evaluate their relative cardiotoxicity. At least one randomized clinical trial examining the relative efficacy and cardiotoxicity of PL-DOX and doxorubicin is underway [30] .
Conclusions
This study demonstrated that 20 mg/m 2 of a pegylated, liposomal formulation of doxorubicin (PL-DOX) administered every iwo weeks induced fewer histologic changes in the hearts of patients with Kaposi's sarcoma than would be expected from the use of conventional doxorubicin in a dose schedule of either 60 mg/m 2 every three weeks or 20 mg/m 2 weekly. Myocardial biopsy was associated with no significant morbidity and no mortality, and because of the specificity and sensitivity of the method, relatively few patients were required to detect the reduction in cardiac toxicity in PL-DOX patients. This apparent advantage may be due to pharmacokinetic changes that result from formulation in a pegylated liposome, but the benefits of this formulation are obfuscated by differences between the PL-DOX patients and historical controls, particularly with regard to anthracycline dose-schedule. Further trials examining the cardiotoxicity of PL-DOX are underway.
